DecImmune Therapeutics, Inc.

DecImmune Therapeutics, Inc. is a biotechnology firm focused on developing and commercializing therapeutic solutions that target immune-mediated diseases, particularly through monoclonal antibodies aimed at treating autoimmune disorders and specific cancers. Formed in 2001 and headquartered in Boston, US, DecImmune Therapeutics, Inc. develops innovative therapies targeting immune responses.

In April 2013, the company was acquired by DSM Pharmaceutical Products. The founders' background details are not disclosed, and there is no mention of subsidiaries or additional funding rounds aside from the latest funding. DecImmune specializes in the development and commercialization of innovative therapeutic solutions targeting immune-mediated diseases. The company’s core offerings include a range of monoclonal antibody products designed to modulate immune responses, which are particularly relevant in the treatment of autoimmune disorders and certain types of cancer.

These therapies aim to enhance the efficacy of immune function while minimizing adverse effects, addressing significant unmet medical needs within the healthcare sector. DecImmune serves a diverse client base that includes healthcare providers, research institutions, and pharmaceutical companies across key geographical markets, including North America, Europe, and Asia-Pacific. The company’s products have been strategically designed to cater to both clinical applications and preclinical research, ensuring their relevance across multiple stages of drug development. DecImmune generates revenue primarily through a business-to-business (B2B) model, engaging in partnerships with pharmaceutical firms and healthcare organizations for the distribution of its therapeutic products.

The company’s transaction structure often involves licensing agreements and collaborative research partnerships, allowing clients access to proprietary technologies and drug candidates. Revenue streams may also include royalties from product sales and milestone payments associated with successful clinical trials. Specific pricing plans are aligned with the complexity and development stage of their offerings, particularly their flagship monoclonal antibodies, which may be priced according to the therapeutic value they provide in clinical settings. This structured approach to revenue generation supports Decimmune's growth trajectory within the competitive landscape of biotechnology.

DecImmune plans to leverage recent funding of USD 2. 25 mn obtained in April 2013 to support the development of new monoclonal antibodies and expand its market reach, targeting North America, Europe, and Asia-Pacific by 2015. This funding will facilitate ongoing research and development initiatives to enhance its product portfolio and solidify partnerships with healthcare providers and pharmaceutical companies.